Telix Pharmaceuticals Ltd — AGM Information 2024

May 21, 2024

==> picture [144 x 59] intentionally omitted <==

Telix Manufacturing Solutions in Belgium

TLX101-CDx PET image showing uptake in glioblastoma

TLX250 SPECT image showing uptake in CAIX-positive lesions

illustration showing TLX591 binding to PSMA

Important information

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this presentation together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this presentation, whether as a result of new information, future developments or a change in expectations or assumptions.

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA), the U.S. Food and - - Drug Administration (FDA), and Health Canada. Full United States prescribing information for Illuccix® can be found at http://illuccixhcp.com/s/illuccix prescribing information.pdf

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Board of Directors. Unless otherwise stated, all figures are in AU$.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Illuccix®, Zircaix® and Pixclara names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Zircaix® and Pixclara are trade names subject to final regulatory approval.

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

Genevieve Ryan Company Secretary

==> picture [291 x 290] intentionally omitted <==

==> picture [73 x 30] intentionally omitted <==

Voting and questions

• A poll will be conducted on all resolutions

• Vote at any time during the course of the meeting

• The Virtual Meeting Online Guide provides detailed steps on how to vote and ask questions online – audio and written

• Chairman intends to vote all undirected votes in favour of the resolutions

• Poll results can be obtained later today by visiting the Company's website or the ASX

• Shareholders and proxies will be invited to ask questions

==> picture [350 x 339] intentionally omitted <==

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

H Kevin McCann AO Chairman

==> picture [291 x 290] intentionally omitted <==

==> picture [73 x 30] intentionally omitted <==

Board of Directors

==> picture [129 x 129] intentionally omitted <==

==> picture [129 x 129] intentionally omitted <==

H Kevin McCann AO Christian

Behrenbruch

Non-Executive Director and Managing Director Chairman and Group CEO

==> picture [128 x 129] intentionally omitted <==

Tiffany Olson

Non-Executive Director

==> picture [129 x 129] intentionally omitted <==

Jann Skinner Non-Executive Director

==> picture [128 x 129] intentionally omitted <==

==> picture [129 x 127] intentionally omitted <==

Andreas Kluge

Mark Nelson

Non-Executive Non-Executive Director Director

==> picture [73 x 30] intentionally omitted <==

Meeting agenda

01

Chairman’s address

02

CEO’s address

03

Formal items of business, including voting and questions

==> picture [73 x 30] intentionally omitted <==

Annual General Meeting of Shareholders Chairman’s address H Kevin McCann AO

==> picture [73 x 30] intentionally omitted <==

==> picture [457 x 540] intentionally omitted <==

==> picture [73 x 30] intentionally omitted <==

TLX250-CDx PET positive scan showing CAIX expression (Phase III ZIRCON study)

A global leader in theranostics and precision medicine A unique, integrated radiopharma business

Therapeutics

Late-stage assets preparing for pivotal trials in prostate, kidney and brain cancer Earlier stage assets include potential alpha therapies

==> picture [156 x 32] intentionally omitted <==

----- Start of picture text -----

Telix Manufacturing
Solutions
----- End of picture text -----

Precision medicine

Advanced imaging (diagnostics) informs treatment pathways and patient selection for therapy

==> picture [167 x 68] intentionally omitted <==

Vertically-integrated, expanding global manufacturing footprint Radioisotope supply

Medical technologies

Integrated Theranostic Approach See it. Treat it. Deep radiopharma expertise Broad development toolkit developing first-in-class or best-in-class products Isotope agnostic (both alpha- and beta- emitters) Validated and novel clinical targets

Deep partner relationships and a global supply chain

Interventional oncology drives deeper customer engagement AI platform / dosimetry software

Access to raw materials

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

10
----- End of picture text -----

Therapeutics: Three key areas of focus Markets with clear opportunities for radiation oncology to fulfil unmet medical needs

==> picture [796 x 399] intentionally omitted <==

----- Start of picture text -----

Urologic Oncology Musculoskeletal Neuro-oncology
Major market opportunity Potential for first-mover Opportunity to innovate
across prostate, kidney advantage in an area of in an established market
and bladder cancer high unmet need for radiation oncology
Bone marrow
Bone metastases
conditioning/palliation
----- End of picture text -----

Precision medicine portfolio

Advanced imaging is a key enabler of therapeutic development

How advanced imaging supports our therapeutic portfolio:

• ⚫ “Companion” for each therapeutic target

• ⚫ Facilitates patient selection for therapy > optimisation of clinical trials and possible requirement for approved product

• ⚫ Validates targets and derisks development and regulatory process for therapeutics

• ⚫ Compact clinical trials , faster path to market

• ⚫ Early revenue generation and commercial team specialisation to support therapeutics business

==> picture [156 x 80] intentionally omitted <==

==> picture [156 x 79] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [156 x 80] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Innovative PSMA imaging product

Cornerstone of urology franchise, requisite for PSMA-targeting therapy

Targets CAIX, highly expressed in ccRCC and multiple hypoxic tumours

Initial focus in post-treatment monitoring, with potential to expand

Expands access / patient reach for PSMA imaging, NDA filing H1 2024

==> picture [73 x 30] intentionally omitted <==

1. Brand name subject to final regulatory approval

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

12
----- End of picture text -----

Our precision medicine model in prostate cancer Imaging, devices and therapeutics across the care continuum

==> picture [915 x 381] intentionally omitted <==

----- Start of picture text -----

68Ga / 99mTc
imaging TLX591:
TLX591
Lutetium ( [177] Lu)
rosopatamab tetraxetan Targeting a cancer 177Lu-PSMA-617
(mCRPC) patient-centric
Current approved
differentiated therapeutic
177Lu-PSMA
profile in first and second
line metastatic castrate therapy in
mCRPC
resistant prostate
TLX090
PSA
TLX592 ( [225] Ac)
level
Clinically Rising PSA mCRPC mCRPC mCRPmCRPC mCRPC
Localised Primary BCR mCSPC 1 [st] Line 2 [nd] Line 3 [rd] Line4 [th] Line 4 [th] Line
Disease nMHSPC
Abiraterone Abiraterone Cabazitaxel Carboplatin
nmCRPC enzalutamide enzalutamide docetaxel re-challenge
docetaxel docetaxel 177Lu-PSMA-617
----- End of picture text -----

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

13
----- End of picture text -----

Telix Manufacturing Solutions

Vertical integration of supply chain and manufacturing

Vancouver

Equipped to deliver patient doses globally

Liege Isotope production patient doses globally Quality control (ARTMS) Herstal ⚫ Global supply chain Angleton (TX) GMP and secondary packaging Bioconjugation / ⚫ In-house EU isotope processing Brussels South Global market forecast to grow production facilityproduction facility (IsoTherapeutics) GMP manufacturing / R&D by 19% per annum to reach US$35B in 2031 Sacramento (CA) ⚫ “AlphaLab” for Clinical doses and specialty R&D process development (Optimal Tracers) Melbourne ⚫ Radiochemistry and Hotlab / dosimetry clinical dose production Global production, process development and R&D sites

⚫ In-house EU Global market forecast to grow production facilityproduction facility by 19% per annum to reach

Continuing to invest in in-house development and production capacity

⚫ U.S. and EU

Global markisotop e t forecas produc ion t to grow by 19% per annum to footprint reach US$35B in 2031 ⚫ End-to-end process development and manufacturing technologies

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

14
----- End of picture text -----

Financial performance

Cash generation funding development of the pipeline

==> picture [892 x 376] intentionally omitted <==

----- Start of picture text -----

2023 Key metrics
Quarterly Revenue, including Q1 2024 [1]
Revenue growth 214%
200.0 Q1 2024
180.0 +75% 175.0 $502.5M ($160.1M 2022)
160.0
140.0 148.1
Gross margin improved
120.0 133.6
120.7
100.0
100.1
63%
80.0
(59%2022)
60.0
40.0
Profit after tax
20.0
0.0
Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024
$5.2M
(Net loss $104.1M 2022)
Total Revenue (AUD)
----- End of picture text -----

==> picture [73 x 30] intentionally omitted <==

1. Q1 2024 revenues are unaudited, preliminary and based on management’s estimate as of the date of this presentation and are subject to completion of the Company’s financial closing procedures.

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

15
----- End of picture text -----

Recent achievements

ProstACT GLOBAL Phase III IND cleared for prostate cancer therapy trial commencement in the U.S.

Clinical differentiation and safety profile of TLX591 confirmed in ProstACT SELECT

Advance next-generation alpha theranostics

Proof of concept established for TLX592 , alpha therapy candidate for prostate cancer

Ethics approval pending to commence biodistribution study for TLX300 program

Recruiting therapeutic trials of TLX250 (kidney) and TLX101 (brain)

Expansion of global manufacturing facilities: Optimal Tracers (U.S.) and production facility in Brussels South

North American production and

processing enhanced with acquisitions of ARTMS and IsoTherapeutics

==> picture [73 x 30] intentionally omitted <==

1. Brand name subject to final regulatory approval. .

Biologics License Application

(BLA) for Zircaix®[1] commenced

Pixclara 1 for brain cancer (glioma) imaging granted Fast Track designation

New Drug Application (NDA) for new PSMA imaging product filing H1

Near-term catalysts

==> picture [621 x 182] intentionally omitted <==

----- Start of picture text -----

Progress Advance next
Expand
late-stage generation
commercial
therapeutic alpha
imaging
pipeline theranostics
portfolio
2024
----- End of picture text -----

==> picture [131 x 131] intentionally omitted <==

----- Start of picture text -----

Verticall y
integrate
supply chain
----- End of picture text -----

H1 2025

ProstACT SELECT (TLX591) rPFS[1] data

Zircaix®[2] (TLX250-CDx) BLA completion

IPAX-2 and IPAX-Linz (TLX101) therapy studies readouts

STARLITE (TLX250 + immunotherapy) Phase 2 readout TLX300 clinical program commences in soft tissue sarcoma ProstACT GLOBAL recruitment at U.S. sites

Pixclara 2 (TLX101-CDx) NDA submission

Illuccix® Brazil, EU and UK approval decisions

New PSMA imaging product NDA submission

ProstACT GLOBAL (TLX591) Ph 3 interim readout TLX592 “alpha” therapeutic trial update

==> picture [73 x 30] intentionally omitted <==

1. Radiographic progression-free survival 2. Brand name subject to final regulatory approval.

.

Thank you

==> picture [73 x 30] intentionally omitted <==

18